The short version of GRF(1-29) fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-20 and is reviewed periodically as new material appears.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis. Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
On January 1, 2026, The Daily Beast described Trump as "sick and sleepy," noting his recent history of dozing during public appearances and a recent report revealing how he was requesting to now attend "fewer, more important meetings. Trump would also concede in an interview with The Wall Street Journal that he was now taking a larger dosage of aspirin and ignoring medical advice. United States Secretary of Health and Human Services Robert F. Kennedy Jr. described Trump's diet as "unhinged" and highly unhealthy in a January interview. Kennedy claimed the president ate high-price premium meals when living at Mar-a-Lago or the White House, but switched to a heavy diet of fast food and candy when travelling. The president apparently had a preference for McDonald's and other major American chains, as he considered corporate restaurants more trustworthy. Kennedy concluded that Trump would need an inhuman constitution to maintain such a lifestyle, stating "I don't know how he's alive, but he is". The Greenland Crisis has brought particular attention to Trump's fitness and stability regarding his international conduct. Following the publicizing of the "Dear Jonas" letter, in which Trump demanded "complete and total control of Greenland" and cited his perceived snub of the 2025 Nobel Peace Prize as a deciding factor in his escalation of the crisis, Democratic lawmakers widely questioned Trump's mental fitness for office.
== Etymology and pronunciation == The word purpura () comes from Latin purpura, "purple", which came from ancient Greek πορφύρα. Purpura is a mass noun naming the condition or state, not the name of an individual spot (thus there is no *purpurum, *purpura or *purpura, *purpurae count declension).
== Research == He investigated the derivatives of phenylhydrazines, establishing their relation to the diazo compounds, and he noted the readiness with which they entered into combination with other substances, giving origin to a wealth of hitherto unknown compounds. Of such condensation products undoubtedly the most important are the hydrazones, which result from the interaction with aldehydes and ketones. His observations, published in 1886, that such hydrazones, by treatment with hydrochloric acid or zinc chloride, yielded derivatives of indole, the parent substance of indigo, were a confirmation of the views advanced by von Baeyer on the subject of indigo and the many substances related to it. He next turned to the fuchsine (then called "rosaniline") magenta dyes, and in collaboration with his cousin Otto Fischer, he published papers in 1878 and 1879 which established that these dyes were derivatives of triphenylmethane. Emil Fischer's next research was concerned with compounds related to uric acid. Here the ground had been broken by von Baeyer, but Fischer greatly advanced the field of knowledge of the purines. In 1881 and 1882 he published papers which established the formulae of uric acid, xanthine, caffeine (achieving the first synthesis), theobromine and some other compounds of this group. After purine itself was isolated, a variety of derivatives were prepared, some of which were patented in view of possible therapeutical applications. Fischer is particularly noted for his work on sugars.
Sources: en.wikipedia.org
=== Persian period === In 537–520 BCE, Zerubbabel became Yehud's governor and started work on the Second Temple, which was stopped. In 520–516 BCE, Haggai and Zechariah goaded the Judahites to resume work on the Temple. Upon completion, Joshua became its high priest. In 458–433 BCE, Ezra and Nehemiah led another group of Judahites to Yehud, with Artaxerxes's permission. Nehemiah rebuilt the temple after some unspecified disaster and removed foreign influence from the Judahite community. That said, some Judahites elected to stay in Persia, where they almost faced annihilation. This period is covered by the entirety of the Book of Ezra, Book of Nehemiah, the Book of Esther, the Book of Haggai, the Book of Zechariah, and the Book of Malachi.
After the death of Ferdinand I in 1825 and the brief reign of his son Francis I, 20-year-old Ferdinand II (son of Francis I) ascended the throne in 1830. He enacted partial economic and administrative reforms:
== Technology and AI == In July 2025, Eucalyptus Health announced a partnership with AI healthcare platform Amigo to integrate AI-powered health agents into its telehealth services, including an AI assistant deployed for the Juniper weight management clinic. The AI tools were intended to support functions such as patient triage, care coordination and health coaching alongside clinician-led care. Juniper introduced an AI chatbot, June, to provide automated guidance on topics such as nutrition, medication use, and weight-loss plateaus. Mental-health and psychology experts cautioned that AI use in weight-management services required strong safeguards to avoid risks to vulnerable patients, including those with eating-disorder histories.
The resulting roGFP variants, named roGFP1-R1 through roGFP1-R14, are much more suitable for live-cell imaging. The roGFP1-R12 variant has been used to monitor redox potential in bacteria and yeast, but also for studies of spatially-organized redox potential in live, multicellular organisms such as the model nematode C. elegans. In addition, roGFPs are used to investigate the topology of ER proteins, or to analyze the ROS production capacity of chemicals.
His political activism prompted the US State Department to deny him a passport in 1952, when he was invited to speak at a scientific conference in London. In a speech before the US Senate on June 6 of the same year, Senator Wayne Morse publicly denounced the action of the State Department, and urged the Passport Division to reverse its decision. Pauling and his wife Ava were then issued a "limited passport" to attend the conference. His full passport was restored in 1954, shortly before the ceremony in Stockholm where he received his first Nobel Prize. Joining Einstein, Bertrand Russell and eight other leading scientists and intellectuals, he signed the Russell-Einstein Manifesto issued July 9, 1955. He also supported the Mainau Declaration of July 15, 1955, signed by 52 Nobel Prize laureates. In May 1957, working with Washington University in St. Louis professor Barry Commoner, Pauling began to circulate a petition among scientists to stop nuclear testing. On January 15, 1958, Pauling and his wife presented a petition to United Nations Secretary General Dag Hammarskjöld calling for an end to the testing of nuclear weapons. It was signed by 11,021 scientists representing fifty countries. In February 1958, Pauling participated in a publicly televised debate with the atomic physicist Edward Teller about the actual probability of fallout causing mutations. Later in 1958, Pauling published No more war!, in which he not only called for an end to the testing of nuclear weapons but also an end to war itself.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.